Two Hilton Court
Parsippany
NJ
07054
USA
(973) 359-2600
Product Categories
Related Content
May 6, 2015 — People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent ...
May 06, 2015
January 12, 2015 — Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ...
January 13, 2015January 14, 2014 — Daiichi Sankyo Company Ltd. announced results from the Phase 3 ENGAGE AF-TIMI 48 study [1]. The ...
January 14, 2014December 6, 2012 — Daiichi Sankyo Inc. and Eli Lilly and Co. announced results of two retrospective, observational ...
December 06, 2012
November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are ...
November 02, 2012September 6, 2012 — Daiichi Sankyo Co. Ltd. and Eli Lilly and Co. announced data from the TRILOGY ACS study, a phase III ...
September 06, 2012
Feature | Antiplatelet and Anticoagulation Therapies| Nicole Fornell, Pharm D
The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus ...
August 28, 2012
January 23, 2012 — A collection of real-life data from 5,000 atrial fibrillation (AF) patients across seven countries ...
January 23, 2012
August 18, 2011 — The antiplatelet agent prasugrel (trade name Effient), in combination with aspirin, was associated ...
August 19, 2011December 29, 2010 – Patient enrollment has been completed for a Phase III trial of an oral Factor Xa inhibitor. The ...
December 29, 2010